22 Results for "

body fat mass

" in MedChemExpress (MCE) Product Catalog:
Products (22)

22 Results for "body fat mass" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-N2840
CAS No.: 488-44-8
Synonyms: Allodulcitol
Allitol (Allodulcitol) is an orally active rare sugar alcohol found in Itea virginica L, Tylopilus plumbeoviolaceus. Allitol has anti-obesity and hypoglycaemic activities. Allitol reduces carcass and total body fat mass, increases cecal weight, surface area, and short-chain fatty acid production, and upregulates cecal microbial enzymes linked to butyrate metabolism. Allitol can be used for the researches of obesity and diabetes .
loading...
    loading...
Cat. No.: HY-P10798
CAS No.: 2883634-40-8
Synonyms: LY-3841136
Research Areas:  

Metabolic Disease

Eloralintide (LY-3841136) is an amylin receptor agonist with human AMY1R EC50 23.9 pM and human AMY3R EC50 253.8 pM. Eloralintide induces decreased appetite, reduced food intake, body weight and fat mass loss, prolonged plasma calcium 2+ reduction, and weak conditioned taste avoidance. Eloralintide can be used for the research of obesity .
loading...
    loading...
Cat. No.: HY-P11245A
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

NN1213 acetate, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 acetate significantly reduces food intake and fat mass. NN1213 acetate can reduce body weightin diet-induced obese rats. NN1213 acetate can be used for the research of obesity .
loading...
    loading...
Cat. No.: HY-P11245
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity .
loading...
    loading...
Cat. No.: HY-P11291A
Research Areas:  

Metabolic Disease

NNC0165-1273 TFA is a selective NPY Y2 receptor agonist with a Ki of 2 nM and an EC50 of 5.0 nM. NNC0165-1273 TFA blocks Ghrelin-induced cFos expression. NNC0165-1273 TFA reduces nocturnal food intake, attenuates feeding behavior, induces early satiety, and causes dose-dependent decreases in body weight and fat mass in diet-induced obese mice. When used in combination with Semaglutide (HY-114118), NNC0165-1273 TFA reduces preference for high-fat diet, promotes body weight loss, and produces sustained weight loss effects in diet-induced obese rats. NNC0165-1273 TFA can be used in studies related to diet-induced obesity .
loading...
    loading...
Cat. No.: HY-120872
CAS No.: 1853130-05-8
Purity:  99.15%
Target:  

Glycosyltransferase

Research Areas:  

Metabolic Disease

AJS1669 free acid is a potent and orally available glycogen synthase (GS) activator. AJS1669 improves glucose metabolism and reduces body fat mass in mice[1].
loading...
    loading...
Cat. No.: HY-W127851
CAS No.: 19953-58-3
Synonyms: Cypridina luciferin analog
CLA, or conjugated linoleic acid, is a polyunsaturated fatty acid that occurs naturally in a variety of animal products, such as meat and dairy. It has several potential benefits for human health, including the ability to reduce body fat mass, improve insulin sensitivity, and reduce inflammation. CLA has been extensively studied for its effects on weight loss and muscle growth, as well as its potential role in preventing chronic diseases such as heart disease and cancer. Additionally, it can be taken as a dietary supplement in capsule form.
loading...
    loading...
Cat. No.: HY-P11262
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC50 value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC50 value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes .
loading...
    loading...
Cat. No.: HY-180642
CAS No.: 3052978-35-2
Research Areas:  

Metabolic Disease

THR-β modulator-3 (Compound 75-2) is a THR-β modulator. THR-β modulator-3reduces total fat mass, body weight. THR-β modulator-3 improves obesity .
loading...
    loading...
Cat. No.: HY-19656
CAS No.: 262376-75-0
Research Areas:  

Metabolic Disease

HMR1426 is an orally active, potent gastric emptying inhibitor. HMR1426 reduces food intake and the rate of gastric emptying, decreases body weight and fat mass and shows an anorectic potential in rats. HMR1426 has the potential for obesity research .
loading...
    loading...
Cat. No.: HY-161985
Target:  

PPAR

Research Areas:  

Metabolic Disease

PPARγ-IN-3 (compound 9ga) is a potent and orally active PPARγ inhibitor. PPARγ-IN-3 reduces triglyceride (TG) accumulation with low cytotoxicity. PPARγ-IN-3 preventes the excessive growth of body weight and lessened fat mass as well as liver mass, decreases lipid accumulation in the liver and blood. PPARγ-IN-3 has the potential for the research of diet-induced obesity .
loading...
    loading...
Cat. No.: HY-P11291
Research Areas:  

Metabolic Disease

NNC0165-1273 is a selective NPY Y2 receptor agonist with a Ki of 2 nM and an EC50 of 5.0 nM. NNC0165-1273 blocks Ghrelin-induced cFos expression. NNC0165-1273 reduces nocturnal food intake, attenuates feeding behavior, induces early satiety, and causes dose-dependent decreases in body weight and fat mass in diet-induced obese mice. When used in combination with Semaglutide (HY-114118), NNC0165-1273 reduces preference for high-fat diet, promotes body weight loss, and produces sustained weight loss effects in diet-induced obese rats. NNC0165-1273 can be used in studies related to diet-induced obesity .
loading...
    loading...
Cat. No.: HY-N2840S
Synonyms: Allodulcitol-13C
Allitol (Allodulcitol)- 13C is the 13C labeled Allitol (HY-N2840). Allitol is an orally active rare sugar alcohol found in Itea virginica L, Tylopilus plumbeoviolaceus. Allitol has anti-obesity and hypoglycaemic activities. Allitol reduces carcass and total body fat mass, increases cecal weight, surface area, and short-chain fatty acid production, and upregulates cecal microbial enzymes linked to butyrate metabolism. Allitol can be used for the researches of obesity and diabetes .
loading...
    loading...
Cat. No.: HY-N2840R
CAS No.: 488-44-8
Synonyms: Allodulcitol (Standard)
Allitol (Allodulcitol) (Standard) is the analytical standard of Allitol (HY-N2840). This product is intended for research and analytical applications. Allitol is an orally active rare sugar alcohol found in Itea virginica L, Tylopilus plumbeoviolaceus. Allitol has anti-obesity and hypoglycaemic activities. Allitol reduces carcass and total body fat mass, increases cecal weight, surface area, and short-chain fatty acid production, and upregulates cecal microbial enzymes linked to butyrate metabolism. Allitol can be used for the researches of obesity and diabetes .
loading...
    loading...
Cat. No.: HY-11032
CAS No.: 902750-48-5
Target:  

Others

Research Areas:  

Metabolic Disease

SM-350300 is a glucoprotein. SM-350300 stimulates lipolysis in white adipocytes by activating the cyclic AMP (cAMP) pathway, and upregulates the expression of lipolytic enzymes and uncoupling proteins (UCP1, UCP3) in brown adipose tissue (BAT) and white adipose tissue (WAT). SM-350300 reduces body weight by decreasing carcass fat while increasing lean muscle mass in metabolic disorder models. SM-350300 can be used for the study of metabolic disorders including obesity, type 2 diabetes, and cachexia .
loading...
    loading...
Cat. No.: HY-110107
CAS No.: 469861-49-2
Purity:  99.98%
GW438014A is a selective NPY-Y5 receptor competitive antagonist capable of crossing the blood-brain barrier, with IC50 values of 197 nM and 211 nM against human receptors. GW438014A reverses PYY-mediated inhibition of Forskolin (HY-15371)-induced cAMP production, reduces NPY-induced food intake and nocturnal food intake in rodents, decreases body weight gain and fat mass in Zucker rats, and inhibits centrally mediated feeding behavior. GW438014A can be used in research related to obesity and epilepsy .
loading...
    loading...
Cat. No.: HY-P11587
Research Areas:  

Metabolic Disease

BGM1812 is a dual agonist of amylin (hAMY3R) (EC50 = 0.627 nM) and CGRP Receptor (hCTR) (EC50 = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity .
loading...
    loading...
Cat. No.: HY-186096
Research Areas:  

Metabolic Disease

LP-856866 is an orally active ACSL5 inhibitor, with IC50 values of 8 nM and 4 nM against mouse and human ACSL5, respectively, and IC50 values of 6 nM and 17 nM against mouse and human ACSL1, respectively. LP-856866 induces delayed gastric emptying, promotes GLP-1 release, reduces food intake, decreases body weight and body fat mass, preserves lean body mass, improves glucose homeostasis, enhances insulin sensitivity, reduces hepatic lipid accumulation, and lowers serum triglyceride and total cholesterol levels. LP-856866 is applicable to research on diet-induced obesity .
loading...
    loading...
Cat. No.: HY-P11291B
Research Areas:  

Metabolic Disease

NNC0165-1273 acetate is a selective NPY Y2 receptor agonist with a Ki of 2 nM and an EC50 of 5.0 nM. NNC0165-1273 acetate blocks Ghrelin-induced cFos expression. NNC0165-1273 acetate reduces nocturnal food intake, attenuates feeding behavior, induces early satiety, and causes dose-dependent decreases in body weight and fat mass in diet-induced obese mice. When used in combination with Semaglutide (HY-114118), NNC0165-1273 acetate reduces preference for high-fat diet, promotes body weight loss, and produces sustained weight loss effects in diet-induced obese rats. NNC0165-1273 acetate can be used in studies related to diet-induced obesity .
loading...
    loading...
Cat. No.: HY-P11880
Target:  

GCGR

Research Areas:  

Metabolic Disease

LY3324954 is a long-acting, highly selective glucagon receptor (GCGR) agonist. LY3324954 stimulates cAMP production via the hepatic GCGR signaling pathway and induces acute blood glucose elevation, while promoting FGF21 expression in the liver and plasma. LY3324954 reduces body weight and abdominal fat mass, increases energy expenditure, and effectively improves lipid homeostasis, insulin sensitivity, and glucose intolerance. LY3324954 can be used in obesity-related research .
loading...
    loading...